AP-1 confers resistance to anti-cancer therapy by activating XIAP.
Wang Y, Wan GH, Wu YM, Wang HS, Wang HF, Zhang G, Lu LL, Li ZQ, Chan KY, Zhou Y, Cai SH, Qi YF, Du J.
Wang Y, et al. Among authors: li zq.
Oncotarget. 2018 Jan 3;9(18):14124-14137. doi: 10.18632/oncotarget.23897. eCollection 2018 Mar 6.
Oncotarget. 2018.
PMID: 29581832
Free PMC article.